Strata Oncology, Inc.
8170 Jackson Road, Suite A
Ann Arbor
Michigan
48103
United States
Tel: 734-527-1000
Website: http://www.strataoncology.com/
51 articles about Strata Oncology, Inc.
-
Strata Oncology Announces Publication of Analytical and Clinical Validation of StrataNGS® in the Journal of Molecular Diagnostics
9/8/2021
Strata Oncology, Inc today announced results from validation studies demonstrating the reliable performance of the StrataNGS test were published in The Journal of Molecular Diagnostics.
-
Show me the money! This week's who's who of IPOs and financing rounds in the biopharma world.
-
Three major pharmaceutical and biotechnology companies announce the success of their respective funding rounds to support future efforts.
-
Strata Oncology Completes $90 Million Series C Financing
7/28/2021
Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, announced the completion of a $90 million Series C financing, bringing the company's total financing to over $130 million since the company's inception.
-
Strata Oncology Presents Data at ASCO 2021 Showing Comprehensive Genomic and Transcriptomic Profiling Predicts Pan-Tumor Benefit of Pembrolizumab
6/4/2021
Strata Oncology ® , Inc ., a precision oncology company advancing molecular indications for cancer therapies, today announced the results of a study focused on evaluating a novel biomarker approach for immunotherapy
-
Strata Oncology Launches Strata Assistant Epic app to Integrate Precision Oncology into Clinical Practice
5/18/2021
Strata Oncology, Inc ., a precision oncology company advancing molecular indications for cancer therapies, today announced the launch of the Strata Assistant TM app for Epic with Kettering Health Network as its first fully integrated user.
-
Strata Oncology Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
5/4/2021
Strata to present data on comprehensive genomic and transcriptomic profiling in patients with advanced solid tumors
-
Strata Oncology Announces the Strata PATH Trial with Pfizer as First Pharma Partner
3/2/2021
Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, announced the Strata Precision Indications for Approved Therapies, or "Strata PATH," trial.
-
Strata Oncology Accelerates Growth Through Expansion of State-of-the-Art Precision Oncology Lab
12/10/2020
Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced it had completed a significant renovation and expansion of its high-throughput cancer sequencing facility, resulting in
-
Strata Oncology Announces Medicare Coverage of StrataNGS Comprehensive Genomic Profiling Test for Patients with Advanced Solid Tumors
10/27/2020
Strata Oncology, Inc ., a precision oncology company advancing molecular indications for cancer therapies, today announced that Palmetto GBA , a Medicare Administrative Contractor (MAC), has established coverage
-
Strata Oncology Announces Partnership to Broaden Enrollment in Mirati Therapeutics' Clinical Trial of MRTX849, a Novel KRAS G12C Selective Inhibitor
8/13/2020
--Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 for Patients with Advanced Solid Tumors Harboring a KRAS G12C Mutation--
-
Strata Oncology Announces Partnership with BioMed Valley Discoveries to Accelerate Enrollment in ERK Inhibitor Study
7/29/2020
Strata Oncology, Inc., a precision oncology company advancing molecular indications for cancer therapies, today announced it has signed an agreement with BioMed Valley Discoveries,
-
Strata Oncology Partners with Elevation Oncology to Accelerate Enrollment of CRESTONE Study for Patients with Rare NRG1 Gene Fusions
7/21/2020
Phase 2 Trial for Patients with Solid Tumors of Any Origin Bearing NRG1 Fusions
-
Elevation Oncology Emerges from Stealth with $32.5M Series A to Develop Precision Medicines for Tumors Harboring Rare Genetic Driver Alterations
7/21/2020
$32.5M Series A Financing Led by Aisling Capital, Vertex Ventures HC, Qiming Venture Partners USA, Driehaus Capital Management, and BVF Partners
-
Strata Oncology and Collaborators to Present Data at ASCO 2020 Supporting the Use of StrataNGS to Facilitate a Large-Scale Precision Oncology Program
5/14/2020
- Systematic NGS Program, featuring a Molecular Profiling Test Optimized for Small Tumor Tissue, Supports Widespread Implementation of NGS Testing -
-
Strata Oncology and Collaborators to Present Data at ASCO 2020
5/7/2020
Strata Oncology, a precision oncology company advancing molecular indications for cancer therapies, announced three studies highlighting data featuring its comprehensive genomic profiling assay StrataNGSTM will be presented at the 2020 Annual Meeting of the American Society of Clinical Oncology, taking place digitally from May 29 – May 31.
-
Strata Oncology Announces Partnerships with Five Additional Health Systems
7/30/2019
Strata Precision Oncology Network expands to 20 institutions
-
Strata Oncology to Present Interim Data from the Strata Trial at the 2019 American Society of Clinical Oncology Annual Meeting
5/20/2019
Strata Oncology, Inc. announced that data from its Strata Trial, a nationwide observational NGS screening protocol providing no-cost tumor sequencing and clinical trial matching for 100,000 advanced cancer patients, will be presented in a poster at the upcoming 2019 American Society of Clinical Oncology Annual Meeting, taking place in Chicago, IL, from May 31-June 4, 2019.
-
CBT Pharmaceuticals and Strata Oncology Announce Collaboration to Accelerate Development of CBT-101, a c-Met inhibitor, for Patients with Non-Small Cell Lung Cancer and other Solid Tumors
12/10/2018
Strata will exclusively refer Met-amplified, Met-mutation and Met-fusion advanced cancer patients identified through the Strata Trial for enrollment consideration into CBT's clinical development program for CBT-101.
-
Strata Oncology Names Scott A. Tomlins, M.D., Ph.D., Chief Medical Officer
11/8/2018
Strata Oncology today announced the appointment of Scott A. Tomlins, M.D., Ph.D., as the Company's Chief Medical Officer. Dr. Tomlins is a leading molecular pathologist and cancer genomics researcher.